Analysis Tools
mortality/aging
|
• mice infected with L. monocytogenes and treated with polyI:C exhibit decreased IFN-beta production and mortality compared to similarly treated wild-type mice
|
immune system
|
• MOG-treated mice exhibit a 4-fold increase in splenocyte proliferation compared to similarly treated wild-type mice
|
|
• in MOG-treated mice
|
|
• in MOG-treated mice
|
|
• MOG-treated mice exhibit an increase in CD4+ T cells compared to in similarly treated wild-type mice
• MOG-treated mice exhibit a 5-fold increase in the number of IL17-producing CD4+ T cells and a 2-fold increase in IFN-gamma-producing CD4+ T cells compared to similarly treated wild-type mice
|
|
• in MOG-treated mice
|
|
• in MOG-treated mice
|
|
• MOG-treated mice exhibit increased IFN-gamma and TNF serum levels compared to similarly treated wild-type mice
|
|
• polyI:C- or LPS-stimulated macrophages or mice stimulated with LPS and infected with L. monocytogenes produce less IFN-beta than similarly treated wild-type cells or mice
• macrophages infected with the Sendai virus produce less IFN-beta than similarly treated wild-type cells
|
|
• MOG-treated mice exhibit increased IFN-gamma and TNF serum levels compared to similarly treated wild-type mice
|
|
• mice exhibit exacerbated experimental autoimmune encephalomyelitis (EAE) and do not exhibit suppression of EAE symptoms and IFN-beta production by polyI:C treatment unlike similarly treated wild-type mice
• MOG-treated mice exhibit a 4-fold increase in splenocyte proliferation compared to similarly treated wild-type mice
• MOG-treated mice exhibit increased IFN-gamma and TNF serum levels compared to similarly treated wild-type mice
• MOG-treated mice exhibit more cellular infiltration with increased CD4+ and CD8+ T cells, macrophages, B cells, and granulocytes and increased demyelination throughout the spinal cord compared to similarly treated wild-type mice
• MOG-treated mice exhibit a 5-fold increase in the number of IL17-producing CD4+ T cells and a 2-fold increase in IFN-gamma-producing CD4+ T cells compared to similarly treated wild-type mice
|
|
• mice infected with L. monocytogenes and treated with polyI:C exhibit decreased IFN-beta production and mortality compared to similarly treated wild-type mice
|
|
• macrophages infected with the Sendai virus produce less IFN-beta than similarly treated wild-type cells
|
homeostasis/metabolism
|
• MOG-treated mice exhibit increased IFN-gamma and TNF serum levels compared to similarly treated wild-type mice
|
hematopoietic system
|
• MOG-treated mice exhibit a 4-fold increase in splenocyte proliferation compared to similarly treated wild-type mice
|
|
• in MOG-treated mice
|
|
• in MOG-treated mice
|
|
• MOG-treated mice exhibit an increase in CD4+ T cells compared to in similarly treated wild-type mice
• MOG-treated mice exhibit a 5-fold increase in the number of IL17-producing CD4+ T cells and a 2-fold increase in IFN-gamma-producing CD4+ T cells compared to similarly treated wild-type mice
|
|
• in MOG-treated mice
|
|
• in MOG-treated mice
|
cellular
|
• MOG-treated mice exhibit a 4-fold increase in splenocyte proliferation compared to similarly treated wild-type mice
|
